Clinical trial
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV…
NCT00316589 · Bavarian Nordic, Industry · Completed
Key facts
| NCT number | NCT00316589 |
|---|---|
| Title | Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients |
| Official title | A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. |
| Lead sponsor | Bavarian Nordic, Industry |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | IMVAMUNE (MVA-BN) |
| Enrollment | 581 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Apr 21, 2006 |
| Last update posted | Jan 3, 2019 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: